Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
6.21
-0.24 (-3.72%)
At close: Mar 18, 2026, 4:00 PM EDT
6.34
+0.13 (2.09%)
After-hours: Mar 18, 2026, 7:46 PM EDT
Relmada Therapeutics Employees
Relmada Therapeutics had 17 employees as of December 31, 2024. The number of employees decreased by 3 or -15.00% compared to the previous year.
Employees
17
Change (1Y)
-3
Growth (1Y)
-15.00%
Revenue / Employee
n/a
Profits / Employee
-$3,304,385
Market Cap
455.40M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 17 | -3 | -15.00% |
| Dec 31, 2023 | 20 | 6 | 42.86% |
| Dec 31, 2022 | 14 | 4 | 40.00% |
| Dec 31, 2021 | 10 | -4 | -28.57% |
| Dec 31, 2020 | 14 | 8 | 133.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Lyell Immunopharma | 300 |
| Rigel Pharmaceuticals | 174 |
| Entrada Therapeutics | 152 |
| Neumora Therapeutics | 95 |
| enGene Holdings | 82 |
| Aclaris Therapeutics | 73 |
| Prothena Corporation | 67 |
| Lexeo Therapeutics | 61 |
RLMD News
- 6 days ago - Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026 - GlobeNewsWire
- 9 days ago - Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 9 days ago - Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing - GlobeNewsWire
- 9 days ago - Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer - GlobeNewsWire
- 2 months ago - Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications - GlobeNewsWire
- 3 months ago - Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology - GlobeNewsWire
- 4 months ago - Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates - GlobeNewsWire